Back to results
US 2026/0103696 A1Published application
Compositions and methods for adoptive cell therapy for cancer
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid A. SCHEINBERG, Thomas J. GARDNER, Derek S. TAN, Jonghan LEE, Ivo LORENZ
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.
Claims5
A method for preparing immune cells for cancer therapy, comprising isolating immune cells from a donor subject, transducing the immune cells with
- (a) a nucleic acid that encodes a first prodrug converting enzyme, wherein the first prodrug converting enzyme is expressed in the cytoplasm of the immune cell;
- and
- optionally,
- (b) a nucleic acid that encodes (i) a second prodrug converting enzyme, wherein the second prodrug converting enzyme is expressed on the surface of the immune cell or is secreted and/or (ii) a nucleic acid that encodes a receptor that binds to a target antigen and/or a nucleic acid encoding the receptor.
1 more element
A compound of Formula I
- or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
- X is O or NH;
- X2 is N or CH;
- X3 is OH or H;
- W1 is H or NH—R3;
- two of R1, R2, and R3 are H and the remaining R1, R2, and R3 is
- X4 and X5 are each independently O or NH;
- X6 is O, NH, CH2, or C(Me)2;
- R4, R5, R6, R7, and R8 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR13a, —(CH2)2—C(O)OR13b,
- and
- R9, R10, R11, R12, R13, R13a, and R13b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl.
8 more elements
A compound of Formula II
- or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
- X7 and X8 are each independently Cl, Br, I, O—S(O)2CH3, or O—S(O)2-tolyl;
- X9 is —C(O)—O, —C(O)—NH, O, or NH;
- R14 is a bond, alkylene, arylene, aralkylene, heteroarylene, or heteroaralkylene;
- R15 is
- X10 and X11 are each independently O or NH;
- X6 is O, NH, CH2, or C(Me)2;
- X12 is O, NH, CH2, or C(Me)2;
- R16, R17, R18, R19, and R20 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR25a, —(CH2)2—C(O)OR25b,
- and
- R21, R22, R23, R24, R25, R25a, and R25b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl, provided that R21, R22, R23, R24, R25, R25a, and R25B are each independently not tert-butyl.
8 more elements
A compounds of Formula III
- or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
- R55 is
- X35 and X36 are each independently O or NH;
- X37 is O, NH, CH2, or C(Me)2;
- R56, R57, R58, R59, and R60 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR6a, (CH2)2—C(O)OR65,
- and
- R61, R62, R63, R64, R65, R65a, and R65b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl.
4 more elements
A compound that is
- or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof.
Dependencies are inferred from the claim text.